Medtronic‘s (NYSE:MDT) 2.0-mm Resolute Onyx drug-eluting stent has won FDA approval and is set to launch in the U.S., making it the smallest device of its kind on the market.
The stent is designed to treat patients with coronary artery disease who have small vessels. Interventional cardiologists often face challenges treating this patient group with larger, conventional stent technologies, according to Medtronic.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic wins FDA nod for smallest drug-eluting stent on U.S. market appeared first on MassDevice.